567 related articles for article (PubMed ID: 24965506)
1. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
2. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
3. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
[TBL] [Abstract][Full Text] [Related]
4. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
Djomand G; Katzman J; di Tommaso D; Hudgens MG; Counts GW; Koblin BA; Sullivan PS
Public Health Rep; 2005; 120(5):543-8. PubMed ID: 16224987
[TBL] [Abstract][Full Text] [Related]
5. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
[TBL] [Abstract][Full Text] [Related]
6. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.
Talarico L; Chen G; Pazdur R
J Clin Oncol; 2004 Nov; 22(22):4626-31. PubMed ID: 15542812
[TBL] [Abstract][Full Text] [Related]
7. Demographic Disparities in the Federal Drug Approval Process for Allergic Rhinitis Medications.
Liebowitz A; Spielman DB; Schlosser RJ; Stewart MG; Gudis DA
Laryngoscope; 2023 Apr; 133(4):755-763. PubMed ID: 35394648
[TBL] [Abstract][Full Text] [Related]
8. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.
Evelyn B; Toigo T; Banks D; Pohl D; Gray K; Robins B; Ernat J
J Natl Med Assoc; 2001 Dec; 93(12 Suppl):18S-24S. PubMed ID: 11798060
[TBL] [Abstract][Full Text] [Related]
9. Minority Enrollment to Clinical Trials: Road to Increased Access.
Vose J
Oncology (Williston Park); 2021 Mar; 35(3):107. PubMed ID: 33818053
[TBL] [Abstract][Full Text] [Related]
10. Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review.
Tahhan AS; Vaduganathan M; Greene SJ; Alrohaibani A; Raad M; Gafeer M; Mehran R; Fonarow GC; Douglas PS; Bhatt DL; Butler J
JAMA Cardiol; 2020 Jun; 5(6):714-722. PubMed ID: 32211813
[TBL] [Abstract][Full Text] [Related]
11. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities.
Stewart JH; Bertoni AG; Staten JL; Levine EA; Gross CP
Ann Surg Oncol; 2007 Dec; 14(12):3328-34. PubMed ID: 17682824
[TBL] [Abstract][Full Text] [Related]
12. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
Rawson NS
CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
[TBL] [Abstract][Full Text] [Related]
13. Participation in cancer clinical trials: race-, sex-, and age-based disparities.
Murthy VH; Krumholz HM; Gross CP
JAMA; 2004 Jun; 291(22):2720-6. PubMed ID: 15187053
[TBL] [Abstract][Full Text] [Related]
14. Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020.
Lythgoe MP; Krell J; Savage P; Prasad V
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1208-1211. PubMed ID: 33859363
[TBL] [Abstract][Full Text] [Related]
15. HIV/AIDS: a minority health issue.
Cargill VA; Stone VE
Med Clin North Am; 2005 Jul; 89(4):895-912. PubMed ID: 15925655
[TBL] [Abstract][Full Text] [Related]
16. The impact of the globalization of cancer clinical trials on the enrollment of Black patients.
Tharakan S; Zhong X; Galsky MD
Cancer; 2021 Jul; 127(13):2294-2301. PubMed ID: 33682111
[TBL] [Abstract][Full Text] [Related]
17. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
[TBL] [Abstract][Full Text] [Related]
18. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
19. Do Current Lung Cancer Clinical Trials Represent All Patient Populations Including Minorities?
Nemala A; Ullah A; Yacur M; Karim NA
Clin Lung Cancer; 2023 Nov; 24(7):573-580. PubMed ID: 37574437
[TBL] [Abstract][Full Text] [Related]
20. Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review.
Strait A; Castillo F; Choden S; Li J; Whitaker E; Falasinnu T; Schmajuk G; Yazdany J
JAMA Netw Open; 2019 Nov; 2(11):e1914745. PubMed ID: 31722023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
